Anticancer Activity of Aaptos Suberitoides on Glioblastoma Multiforme Cell Line

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2024 May 29

PMID 38809654

Authors

Fathul Huda

Rohim Hermawan

Tenny Putri

Resti Gradia Dwiwina

Afiat Berbudi

Muhammad Hasan Bashari

Affiliations

Soon will be listed here.

Abstract

Objective: Glioblastoma Multiforme (GBM) poses a significant challenge due to its high aggressiveness and unfavorable prognosis, with existing treatments demonstrating limited efficacy in prolonging survival rates. This study aimed to assess the anticancer properties of Aaptos suberitoides extracts and fraction on the U87 cell line, serving as a representative model for GBM.

Methods: U87 cells were treated with ethanol extracts derived from Aaptos suberitoides, specifically two extracts (OAA-1 and OAA-2) and one ethyl acetate fraction (EA) isolated from specimens collected on Pramuka Island and Tinjil Island. The evaluation encompased microscopic observation and MTT assay to determine the IC50. Subsequently, antiproliferative effects were investigated through apoptosis and cell cycle assays.

Results: The extract demonstrated cytotoxic activity against U87 cells, with OAA-1 and OAA-2 exhibiting IC50 values of 35.78 μg/mL and 25.38 μg/mL, respectively. OAA-1 notably induced apoptosis at 50 μg/mL and induced cell cycle arrest. On other hand, OAA-2, while also inducing apoptosis significantly, had a lesser impact on cell cycle arrest. In contrast, EA induced significant apoptosis at a concentration of 100 μg/mL.

Conclusion: The ethanol extracts and the ethyl acetate fraction of Aaptos suberitoides emerged as a promising candidate for Glioblastoma Multiforme cancer therapy, showing potential in inhibiting cell proliferation and inducing apoptosis.

References

Kim M, Woo S, Kim M, Park J, Hwang J . Anti-photoaging effect of aaptamine in UVB-irradiated human dermal fibroblasts and epidermal keratinocytes. J Asian Nat Prod Res. 2014; 16(12):1139-47. DOI: 10.1080/10286020.2014.983092. View

Thacker R, Freeman C . Sponge-microbe symbioses: recent advances and new directions. Adv Mar Biol. 2012; 62:57-111. DOI: 10.1016/B978-0-12-394283-8.00002-3. View

Aoki S, Kong D, Suna H, Sowa Y, Sakai T, Setiawan A . Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner. Biochem Biophys Res Commun. 2006; 342(1):101-6. DOI: 10.1016/j.bbrc.2006.01.119. View

Nastrucci C, Cesario A, Russo P . Anticancer drug discovery from the marine environment. Recent Pat Anticancer Drug Discov. 2012; 7(2):218-32. DOI: 10.2174/157489212799972963. View

Rieger A, Nelson K, Konowalchuk J, Barreda D . Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. J Vis Exp. 2011; (50). PMC: 3169266. DOI: 10.3791/2597. View

Soave C, Guerin T, Liu J, Dou Q . Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. Cancer Metastasis Rev. 2017; 36(4):717-736. PMC: 5722705. DOI: 10.1007/s10555-017-9705-x. View

Wang S, Fu J, Hao H, Jiao Y, Li P, Han S . Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy. Pharmacol Res. 2021; 170:105728. DOI: 10.1016/j.phrs.2021.105728. View

Hanif F, Muzaffar K, Perveen K, Malhi S, Simjee S . Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac J Cancer Prev. 2017; 18(1):3-9. PMC: 5563115. DOI: 10.22034/APJCP.2017.18.1.3. View

Kumar P, Nagarajan A, Uchil P . Analysis of Cell Viability by the MTT Assay. Cold Spring Harb Protoc. 2018; 2018(6). DOI: 10.1101/pdb.prot095505. View

10.

Eferl R, Wagner E . AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003; 3(11):859-68. DOI: 10.1038/nrc1209. View

11.

Ghasemi M, Turnbull T, Sebastian S, Kempson I . The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis. Int J Mol Sci. 2021; 22(23). PMC: 8657538. DOI: 10.3390/ijms222312827. View

12.

Hayon T, Dvilansky A, Shpilberg O, Nathan I . Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia. Leuk Lymphoma. 2004; 44(11):1957-62. DOI: 10.1080/1042819031000116607. View

13.

Xia L, Tan S, Zhou Y, Lin J, Wang H, Oyang L . Role of the NFκB-signaling pathway in cancer. Onco Targets Ther. 2018; 11:2063-2073. PMC: 5905465. DOI: 10.2147/OTT.S161109. View

14.

Trogrlic I, Trogrlic D, Trogrlic D, Trogrlic A . Treatment of glioblastoma with herbal medicines. World J Surg Oncol. 2018; 16(1):28. PMC: 5809810. DOI: 10.1186/s12957-018-1329-2. View

15.

Grochans S, Cybulska A, Siminska D, Korbecki J, Kojder K, Chlubek D . Epidemiology of Glioblastoma Multiforme-Literature Review. Cancers (Basel). 2022; 14(10). PMC: 9139611. DOI: 10.3390/cancers14102412. View

16.

Lu K, Bergers G . Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol. 2013; 2(1):49-65. PMC: 3673744. DOI: 10.2217/cns.12.36. View

17.

Lipchick B, Fink E, Nikiforov M . Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res. 2016; 105:210-5. PMC: 5044866. DOI: 10.1016/j.phrs.2016.01.029. View

18.

Shamloo B, Usluer S . p21 in Cancer Research. Cancers (Basel). 2019; 11(8). PMC: 6721478. DOI: 10.3390/cancers11081178. View

19.

Rajaratnam V, Islam M, Yang M, Slaby R, Ramirez H, Mirza S . Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. Cancers (Basel). 2020; 12(4). PMC: 7226351. DOI: 10.3390/cancers12040937. View

20.

Ostrom Q, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan J . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020; 22(12 Suppl 2):iv1-iv96. PMC: 7596247. DOI: 10.1093/neuonc/noaa200. View